Health Condition 1: null- malignant gliomas
Conditions
Interventions
Intervention1: 25 patients will be provided the ALA for inducing fluorescence.: Prior to surgery all patients would receive freshly prepared solution of 5â??ALA
Medac, Germany (@ 20 mg/kg bodyweight dissolved in 100 ml of potable water) [Stummer et al, 2006] orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surge
Sponsors
Intramural TMC
Eligibility
Inclusion criteria
Inclusion criteria: Per-primum glioma •Adults (18-65 years) •Radiologically suspected malignant gliomas •Variable contrast enhancement on MRI (patchy and/or non-uniform) •Eligible for surgical therapy (craniotomy NOT stereotactic biopsy ) •No contraindication for surgery
Exclusion criteria
Exclusion criteria: •Poor general condition (KPS •Prior treatment (except biopsy) •Compromised renal/hepatic function. •Immunocompromised status •Known photosensitivity / allergy to 5-ALA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Degree of fluorescence in different tumor regions. 2. PPIX quantificationTimepoint: NA | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Proteomics differences in variably fluorescing regions.Timepoint: NA | — |
Countries
India
Contacts
Public ContactDr Prakash Shetty
Tata Memorial Centre TMC Advanced Centre for Treatment Research and Education in Cancer ACTREC
Outcome results
None listed